Georgia Cancer Specialists (GCS) physician Dr. Mansoor Saleh was recently published in the British Journal of Haematology. His abstract about the phase two study of arsenic trioxide in patients with relapsed or refractory multiple myeloma was published in May of 2004, in Volume 125. He also presented a poster he helped author at the American Society of Hematology’s (ASH) 46 th annual meeting in San Diego from December 4-7.
Dr. Saleh was among six physicians who participated in the study, whose focus was to determine if arsenic trioxide, an anti-tumor agent with a multifaceted mechanism of action, would have any effect on late stage multiple myeloma patients.
Dr. Saleh, director of clinical research for GCS, hopes this study will lead to more effective treatments for multiple myeloma patients.
“Hopefully this study we’re doing will give us clues as to how to better treat multiple myeloma patients,” said Dr. Saleh.
In San Diego, at the ASH annual meeting, Dr. Saleh and 10 other researchers presented their poster with findings on another study, “Tositumomab and iodine I 131 Tositumomab (the BEXXAR therapeutic regimen) produced ongoing, durable remissions of more than 4 years in 9 patients with non-Hodgkin’s lymphoma (NHL) in a pivotal study of patients refractory to their last chemotherapy.” The research was an update to the pivotal study of the BEXXAR therapeutic regimen, and it found, after three more years of follow-up, long-term safety data remained basically unchanged, with no further reported cases of hypothyroidism or MDS (myelodysplastic syndrome).
Dr. Saleh practices at the GCS Northside office.